Improving manufacture and commercialisation of a 3D skin model for drug safety

点击翻译按钮获取中文摘要

Alcyomics Ltd, has developed a novel proof of concept human skin equivalent model (Skimune™-3D) from our current patented skin assay (Skimune™). Both assays use healthy volunteer blood and skin samples to assess drugs and compounds for adverse immune reactions. Our objective, using Launchpad funding is to make a reproducable manufacturable Skimune™-3D model with improved scalability and longevity. We will assess the longevity and reproducibility of the new model, using a panel of known positive and negative controls. Using robust protocols with release specifications for manufacture we will test at least ten independent Skimune™-3D batches. New SOPs and testing protocols for Skimune™-3D will be established and validated against the current Skimune™ whole skin assay. Our model is the first 3D skin model capable of assessing adverse immune responses. Working with our existing and NE Process Sector Cluster clients we will trial the new Skimune™-3D assays. We will also avail of the business and market support facilities the Launchpad can offer to access new customers in the Cluster and markets e.g. cosmetic safety testing, toxicology and stratified medicine.